Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 941 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active Comparator 2 Clear all
Completed Phase 3 Interventional Results available

Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV

NCT00035932
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir + ritonavir + tenofovir + nucleoside, Atazanavir + saquinavir + tenofovir + nucleoside, Lopinavir/ritonavir + tenofovir + nucleoside
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
29
States / cities
San Francisco, California • Torrance, California • Boulder, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2010 · Synced Oct 21, 2026, 6:43 PM EDT
Completed Phase 2 Interventional Results available

Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)

NCT00505752
View directory record Official record
Conditions
Infertility
Interventions
AS900672-Enriched 50 microgram (mcg), AS900672-Enriched 100 mcg, AS900672-Enriched 150 mcg, Follitropin alfa 150 international unit (IU), Recombinant human chorionic gonadotropin (r-hCG)
Drug
Lead sponsor
Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 36 Years · Female only
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Oct 21, 2026, 6:43 PM EDT
Completed Phase 1 Interventional

Computerized Attention Training for Individuals With Acquired Brain Injury

NCT01641432
View directory record Official record
Conditions
Acquired Brain Injury, Stroke, Hemispatial Neglect
Interventions
Tonic and Phasic Attention Training, Active Comparator
Behavioral
Lead sponsor
Posit Science Corporation
Industry
Eligibility
21 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Oct 21, 2026, 6:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Enhanced Firefighter Rehab Trial: The Role of Aspirin in Preventing Heat Stress Induced Platelet Activation

NCT01066923
View directory record Official record
Conditions
Heat Stress Disorders
Interventions
Daily aspirin (ASA), Active cooling, Acute aspirin (ASA), Passive cooling, Daily placebo, Acute placebo
Drug · Other
Lead sponsor
Dave Hostler
Other
Eligibility
18 Years to 49 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 21, 2026, 6:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

NCT01975220
View directory record Official record
Conditions
Healthy
Interventions
Empagliflozin/Metformin XR FDC, 25 mg Empagliflozin/1000 mg Metformin XR, FDC, 1 tablet Empagliflozin/2 tablets Metformin XR, 1 tablet Empagliflozin/3 tablets Metformin XR
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 21, 2026, 6:43 PM EDT
Completed Not applicable Interventional Results available

Multi-layer Insoles for a Patient-specific Approach to Shear and Pressure Reduction in Diabetes-related Foot Ulcer

NCT01844479
View directory record Official record
Conditions
Diabetic Foot Ulcer, Diabetic Foot
Interventions
diabetic foot orthotic, Standard innersole
Device · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 21, 2026, 6:43 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study to Assess the Efficacy and Safety of Various Vibrating Capsule Modes

NCT03329027
View directory record Official record
Conditions
Constipation
Interventions
Vibrating Capsule, Sham capsule
Device
Lead sponsor
Vibrant Ltd.
Industry
Eligibility
22 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Canoga Park, California • Albuquerque, New Mexico • Willoughby, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 21, 2026, 6:43 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes

NCT01455870
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ITCA 650 60 mcg/day, sitagliptin
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
50
States / cities
Birmingham, Alabama • Chandler, Arizona • Long Beach, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Oct 21, 2026, 6:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously

NCT00510029
View directory record Official record
Conditions
Arrhythmia
Interventions
GAP-134
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2008 · Synced Oct 21, 2026, 6:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioavailability and Pharmacokinetics of Mango

NCT03365739
View directory record Official record
Conditions
Healthy Subjects
Interventions
Active Comparator 1, Active Comparator 2, Control Comparator
Dietary Supplement
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
20 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 21, 2026, 6:43 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Reversal of Aspirin Antiplatelet Therapy With Cold Stored Platelets

NCT05111028
View directory record Official record
Conditions
Reversal of Platelet Aggregation Inhibitors
Interventions
Autologous Room Temperature stored Platelet transfusion, Autologous Cold Stored Platelet transfusion
Biological
Lead sponsor
Bloodworks
Other
Eligibility
18 Years to 59 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 21, 2026, 6:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)

NCT03950856
View directory record Official record
Conditions
Pneumococcal Infections, Pneumonia, Pneumococcal
Interventions
V114, Prevnar 13™
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
2,340 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
30
States / cities
Chandler, Arizona • Mesa, Arizona • Fountain Valley, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 21, 2026, 6:43 PM EDT
Completed Phase 4 Interventional Results available

Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)

NCT02973477
View directory record Official record
Conditions
Type2 Diabetes, Cardiovascular Diseases
Interventions
Dapagliflozin, Glimepiride
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 21, 2026, 6:43 PM EDT
Completed No phase listed Observational

A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)

NCT06064656
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva (FOP)
Interventions
Non-Interventional
Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 21, 2026, 6:43 PM EDT
Completed Phase 2 Interventional

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

NCT01658501
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
50 mg PB1023, 70 mg PB1023, 100 mg PB1023, Placebo (0.9% Sodium Chloride), Victoza®, Diet and Exercise, Metformin, Sulfonylurea, Metformin and Sulfonylurea
Drug · Other
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
93
States / cities
Anniston, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 21, 2026, 6:43 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacokinetics (PK) Study of Epinephrine Inhalation Aerosol in Healthy Volunteers

NCT01143051
View directory record Official record
Conditions
Asthma
Interventions
epinephrine inhalation aerosol
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 30 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 21, 2026, 6:43 PM EDT
Completed Phase 2 Interventional Results available

Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer

NCT02324335
View directory record Official record
Conditions
Head and Neck Neoplasms, Mucositis
Interventions
Brilacidin, Placebo
Drug · Other
Lead sponsor
Innovation Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
16
States / cities
Gilbert, Arizona • Lakeland, Florida • Columbus, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 21, 2026, 6:43 PM EDT
Completed Phase 1 Interventional Results available

Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes

NCT01933672
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PF-04937319 once-daily, PF-04937319 split-dose, Sitagliptin once-daily
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
8
States / cities
DeLand, Florida • South Miami, Florida • High Point, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 21, 2026, 6:43 PM EDT
Completed Phase 4 Interventional Results available

Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?

NCT00306475
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Divalproex Sodium Extended-Release Tablets, placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 21, 2026, 6:43 PM EDT
Completed Phase 2 Interventional

A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes

NCT00486200
View directory record Official record
Conditions
Herpes Genitalis
Interventions
ASP2151, valacyclovir, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 21, 2026, 6:43 PM EDT
Completed Phase 4 Interventional Results available

Lumbar Plexus vs Quadratus Lumborum Block in Post-operative Pain Following Total Hip Replacement

NCT03801265
View directory record Official record
Conditions
Hip Osteoarthritis
Interventions
Lumbar plexus block, Quadratus lumborum type 3 block, Ropivacaine injection
Procedure · Drug
Lead sponsor
Sharad Khetarpal
Other
Eligibility
18 Years to 90 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 21, 2026, 6:43 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations

NCT02971839
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-561, Placebo, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Oct 21, 2026, 6:43 PM EDT
Completed Phase 2 Interventional Results available

Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)

NCT00604825
View directory record Official record
Conditions
Menopausal and Female Climacteric States
Interventions
Other: Placebo, GSK232802, PREMARIN
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
41
States / cities
Chandler, Arizona • Glendale, Arizona • Scottsdale, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Oct 21, 2026, 6:43 PM EDT
Not listed Phase 1 Interventional

A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

NCT02059564
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
HM11260C, Placebo, Victoza
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
California City, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Oct 21, 2026, 6:43 PM EDT